Products for Research Use Only

Conivaptan

CAT: 0804-HY-18347Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18347Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function[1].
CAS Number
210101-16-9
Product Name Alternative
YM 087 (free base)
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
Vasopressin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/conivaptan.html
Smiles
O=C(C1=C(C2=CC=CC=C2)C=CC=C1)NC3=CC=C(C(N4C5=C(C6=C(CC4)N=C(C)N6)C=CC=C5)=O)C=C3
Molecular Formula
C32H26N4O2
Molecular Weight
498.57
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Wada K, et al., Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507 (1-3) :145-51.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
V1a Receptor ; V2 Receptor
Citation 01
Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomed J. 2020 Aug;43 (4) :368-374.|Dig Dis Sci. 2022 Aug;67 (8) :3683-3692.|Eur J Pharmacol. 2020 Aug 5;880:173157.|Front Pharmacol. 2019 Nov 15;10:1380.|J Med Chem. 2022 Jul 14;65 (13) :9295-9311.|J Med Chem. 2024 Apr 11;67 (7) :5935-5944.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|J Transl Med. 2025 Jan 22;23 (1) :103.|Nat Commun. 2025 Nov 4;16 (1) :9734.|Neurogastroenterol Motil. 2019 Feb;31 (2) :e13493.|SSRN. 2023 May 30.|SSRN. 2025 Jun 18.